ArticleBMC neurology2025
Clinical characteristics and treatment of patients with overlapping MOG and anti-NMDAR encephalitis.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to investigate clinical manifestations, cerebrospinal fluid (CSF) profiles, neuroimaging characteristics, and treatment responses in patients demonstrating concurrent NMDAR antibody (NMDAR-ab) positivity in CSF and MOG antibody (MOG-ab) seropositivity.
methodsA retrospective study was conducted on patients with dual MOG-ab and anti-NMDAR antibody positivity treated at the Department of Neurology and Pediatrics, First Affiliated Hospital of Zhengzhou University (September 2019-July 2023). Participants were categorized into three groups: overlapping antibody group, isolated anti-NMDAR encephalitis, and MOG antibody-associated disease (MOGAD).
resultsThirteen patients with antibody overlap presented with encephalitis spectrum symptoms including fever (53.8%), headache (61.5%), altered consciousness (46.2%), neuropsychiatric disturbances (38.5%), and seizures (23.1%) at disease onset. Cranial MRI revealed cortical/subcortical involvement in 30.8% of cases, with leptomeningeal enhancement observed in 22.2%. Acute-phase treatment predominantly included intravenous methylprednisolone (IVMP) and intravenous immunoglobulin (IVIG). Median modified Rankin Scale (mRS) scores improved significantly from 2 (IQR: 1-2.5) pre-treatment to 1 (IQR: 0.5-1) post-treatment. Compared to MOGAD controls, overlap adult patients exhibited higher ICU admission rates (30.8% vs. 6.7%), increased frequency of neuropsychiatric symptoms (38.5% vs. 6.7%), and lesser cortical/subcortical MRI abnormalities (30.8% vs. 64.4%), with reduced gadolinium enhancement (22.2% vs. 68.2%, P < 0.05). Distinct from isolated anti-NMDAR encephalitis, overlap cases demonstrated lower rates of neuropsychiatric disturbances (38.5% vs. 83.3%) and seizures (23.1% vs. 62.5%), but higher incidence of brachium pontis MRI abnormalities (23.1% vs. 0.0%, P < 0.05). Kaplan-Meier analysis over 6–48 months follow-up showed no significant difference in relapse rates between the overlapping antibody group and the MOGAD group or the anti-NMDAR encephalitis group (log-rank P > 0.05).
conclusionDemographic characteristics and oncological associations were comparable across groups. Overlap cases demonstrated unique clinico-radiological profiles with predominant cortical/subcortical involvement and reduced meningeal enhancement. Neuroimaging evidence of brachium pontis abnormalities in anti-NMDAR encephalitis warrants MOG-ab testing. This Asian cohort demonstrates distinct clinical trajectories compared to Western series, emphasizing the need for regional diagnostic considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.